Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Interest Income

Income earned on cash, deposits, and investments held by the company.

Crescent Biopharma, Inc.NASDAQ: CBIO

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $1.45M rose 669.1% year over year, ahead of the +409.6% change in trailing-twelve-month interest income. Sequentially, it rose 32.1% from the prior quarter. Over 3 fiscal years it compounded at +59.1% a year.

Context

  • Interest income amounted to 26.5% of revenue in FY2025.
  • Interest income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +669.1% holds above the trailing-twelve-month pace of +409.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.45M+32.1% QoQ
Last fiscal yearDec 2025
$2.88M+187.2% YoY
LTMMar 2026
$4.13M+409.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+669.1%——
1 year+187.2%——
3-year CAGR+59.1%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.88M USD
Year-over-year change
+187.2%
4-year CAGR
+247.3%

Interest Income vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +409.6% is the highest of 10, against a peer median of -19.9%.
  • Interest income amounts to 34.8% of revenue for CBIO, versus a peer median of 10.2%.
CBIO Competitors
Interest Income for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$58M USD+23.4%+36.8%49.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.4M USD-19.9%+114.3%22679.5%
ZYMEZymeworks Inc.LTM Sep 2026$11.45M USD-20.8%+54.9%4.3%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥8.02M CNY+48.7%-39.7%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$7M USD+5.2%+39.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$5.74M USD-2.6%+45.8%16.2%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$4.13M USD+409.6%+59.1%34.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.94M USD-26.6%+83.4%—
CGENCompugen Ltd.LTM Mar 2026$2.66M USD-49.0%+45.3%3.7%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —-19.9%+45.3%10.2%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.